NRAS and cutaneous melanoma: Hyperactivation of the MAPK (mitogen-activated protein kinase) RAF/MEK/ERK signaling pathway is commonly observed in cutaneous melanomas due to NRAS or BRAF mutations [3,4], and systemic treatment in these cases may include BRAF and MEK inhibitors.